Alliance Wealth Advisors LLC UT Cuts Stake in Gilead Sciences, Inc. $GILD

Key Points

• Alliance Wealth Advisors LLC UT reduced its position in Gilead Sciences by 31.7% in Q4, selling 9,157 shares and leaving it with 19,711 shares valued at about $2.42 million.
• Insiders have been selling: CFO Andrew D. Dickinson and Johanna Mercier each sold 3,000 shares at $140.96 on April 15 under pre-arranged Rule 10b5-1 plans, and insiders have sold a total of 178,640 shares (~$26.6M) in the last 90 days (insiders own 0.30%).
• Gilead beat Q4 estimates (EPS $1.86 vs. $1.83; revenue $7.93B vs. $7.68B), set FY2026 EPS guidance of 8.45–8.85, raised its quarterly dividend to $0.82 (annual $3.28, ~2.5% yield), and retains a consensus analyst rating of a Moderate Buy with a $157.35 target.

Alliance Wealth Advisors LLC UT lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,711 shares of the biopharmaceutical company's stock after selling 9,157 shares during the period. Alliance Wealth Advisors LLC UT's holdings in Gilead Sciences were worth $2,419,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Csenge Advisory Group grew its position in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock valued at $2,375,000 after purchasing an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock worth $8,713,000 after buying an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. lifted its stake in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock valued at $1,115,000 after buying an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd lifted its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at approximately $1,274,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider directly owned 128,779 shares of the company's stock, valued at approximately $18,152,687.84. The trade was a 2.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 178,640 shares of company stock valued at $26,584,250. 0.30% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.8%

NASDAQ GILD opened at $132.69 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $95.29 and a 12 month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a 50 day moving average of $140.49 and a 200-day moving average of $132.55. The company has a market cap of $164.70 billion, a PE ratio of 19.60, a PEG ratio of 1.74 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is currently 48.45%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GILD shares. Truist Financial increased their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Oppenheimer increased their target price on Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Wall Street Zen raised Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 14th. Finally, TD Cowen boosted their price target on Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.